Our Platform

Science Built. Clinically Oriented.

The AlbuDerm Albumin-Based Filler Platform

The AlbuDerm platform leverages recombinant human albumin as a next generation biomaterial scaffold for injectable aesthetic applications. All AlbuDerm programs are currently at the preclinical or conceptual stage. All programs are intended for future clinical evaluation.

The AlbuDerm Albumin-Based Filler Platform

A Platform Engineered for Performance

Our platform is engineered to create injectable biostimulator fillers with tunable material properties, controlled integration, and a strong foundation in protein science. By starting with a well-characterized human protein, we aim to build a predictable, adaptable, and clinically relevant foundation for future aesthetic and regenerative applications.

Our Platform Architecture

Albumin atthe Core

Recombinant human albumin is being evaluated as a potential commercial scaffold material. Its sourcing, comparability, suitability and performance remain under development.

EngineeredMaterial Properties

Through molecular level design and controlled crosslinking, the platform aims to tune viscoelasticity, firmness, and degradation behavior.

Purified &Standardized

Development emphasizes high purity inputs, controlled processing, and robust analytical characterization to support consistency and quality.

InjectablePerformance

Formulations are being optimized in preclinical work for syringeability, handling, and structural support aligned with aesthetic injection workflows.

Clinician &Patient Focused

Product concepts are shaped around real world clinical practice, with the goal of supporting predictable, reproducible outcomes in future clinical evaluation.

Built for the Next Generation

One Biomaterial Foundation, Multiple Development Pathways.

While the initial focus is an aesthetic medical filler, the albumin scaffold is being explored for additional future applications, including:

Regenerative medicineSoft tissue supportDrug delivery concepts

All exploratory programs remain at the preclinical or conceptual stage.

Key Platform Features

RecombinantHuman Albumin

A well studied protein backbone used in other medical settings.

High Purity& Consistency

Development centered on tight process control and analytical rigor.

Tunable MaterialProperties

Designed to allow adjustment of firmness, persistence, and integration characteristics.

ClinicallyRelevant Design

Intended to align with how aesthetic injectables are used in practice.